S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
With oil prices slumping, OPEC+ producers weigh more production cuts
66,000% upside on tiny biotech? (Ad)
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
66,000% upside on tiny biotech? (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:STIM

Neuronetics (STIM) Stock Forecast, Price & News

$2.71
-0.06 (-2.17%)
(As of 06/2/2023 ET)
Compare
Today's Range
$2.62
$2.85
50-Day Range
$2.07
$2.93
52-Week Range
$2.01
$6.95
Volume
55,198 shs
Average Volume
176,439 shs
Market Capitalization
$77.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.67

Neuronetics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
256.7% Upside
$9.67 Price Target
Short Interest
Healthy
1.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$556,473 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.29) to ($0.98) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

228th out of 983 stocks

Surgical & Medical Instruments Industry

24th out of 97 stocks


STIM stock logo

About Neuronetics (NASDAQ:STIM) Stock

Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. It operates through United States and International geographical segments. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.

Receive STIM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuronetics and its competitors with MarketBeat's FREE daily newsletter.

STIM Stock News Headlines

“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
Neuronetics names Lisa Metzner-Rosas as CMO
Neuronetics, Inc. (NASDAQ:STIM) Short Interest Update
See More Headlines

STIM Price History

STIM Company Calendar

Last Earnings
5/09/2023
Today
6/04/2023
Next Earnings (Estimated)
8/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:STIM
Employees
175
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.67
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+256.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-37,160,000.00
Pretax Margin
-55.35%

Debt

Sales & Book Value

Annual Sales
$65.21 million
Book Value
$1.70 per share

Miscellaneous

Free Float
26,376,000
Market Cap
$77.10 million
Optionable
Not Optionable
Beta
1.93

Key Executives

  • Keith J. SullivanKeith J. Sullivan
    President, Chief Executive Officer & Director
  • Stephen FurlongStephen Furlong
    Chief Financial Officer, Treasurer & Executive VP
  • Cory Anderson
    SVP- Research & Development & Clinical Affairs
  • W. Andrew Macan
    Secretary, CCO, EVP & General Counsel
  • Sara Grubbs
    Chief Revenue Officer & Senior Vice President













STIM Stock - Frequently Asked Questions

Should I buy or sell Neuronetics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STIM shares.
View STIM analyst ratings
or view top-rated stocks.

What is Neuronetics' stock price forecast for 2023?

2 brokers have issued twelve-month price objectives for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.67 in the next year. This suggests a possible upside of 256.7% from the stock's current price.
View analysts price targets for STIM
or view top-rated stocks among Wall Street analysts.

How have STIM shares performed in 2023?

Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM shares have decreased by 60.6% and is now trading at $2.71.
View the best growth stocks for 2023 here
.

Are investors shorting Neuronetics?

Neuronetics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 304,200 shares, a decrease of 19.8% from the April 30th total of 379,400 shares. Based on an average daily trading volume, of 253,300 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.2% of the company's shares are sold short.
View Neuronetics' Short Interest
.

When is Neuronetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our STIM earnings forecast
.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.01. The company had revenue of $15.54 million for the quarter, compared to analysts' expectations of $15.11 million. Neuronetics had a negative net margin of 55.34% and a negative trailing twelve-month return on equity of 62.22%.

What ETF holds Neuronetics' stock ?

iShares Neuroscience and Healthcare ETF holds 2,895 shares of STIM stock, representing 0.14% of its portfolio.

What guidance has Neuronetics issued on next quarter's earnings?

Neuronetics issued an update on its second quarter 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.00 million-$18.00 million, compared to the consensus revenue estimate of $17.30 million.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

When did Neuronetics IPO?

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

What is Neuronetics' stock symbol?

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Who are Neuronetics' major shareholders?

Neuronetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cannell Capital LLC (10.99%), Silvercrest Asset Management Group LLC (3.41%), Balyasny Asset Management L.P. (3.25%), Acadian Asset Management LLC (1.46%), BlackRock Inc. (1.33%) and Dimensional Fund Advisors LP (1.31%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends
.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neuronetics' stock price today?

One share of STIM stock can currently be purchased for approximately $2.71.

How much money does Neuronetics make?

Neuronetics (NASDAQ:STIM) has a market capitalization of $77.10 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

How many employees does Neuronetics have?

The company employs 175 workers across the globe.

How can I contact Neuronetics?

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.

This page (NASDAQ:STIM) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -